Insulin Substitution Portugal: Implications of ...

By João L. Carapinha

May 1, 2026

INFARMED has informed healthcare professionals about the upcoming discontinuation of several Novo Nordisk insulin products in Portugal and to provide clear guidance on insulin substitution Portugal. On 30 April 2026, INFARMED issued Circular 04...
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approach...
Gaps in AI Governance Healthcare Frameworks: Ensuring Effective Implementatio...
Enhancing Health Technology Assessment Transparency through Digital Innovation
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometab...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
Establishing a Vaccine Confidence Strategy: EMA’s New Advisory Group Ta...
Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program f...
Medical Device Innovation South Africa: Breaking Down Systemic Barriers
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation